40,000 Chikungunya Vaccines Arriving at France's La Réunion

A substantial Chikungunya outbreak is occurring throughout France's overseas department of La Réunion Island, which has spiked since early 2025, with 8,600 cases recorded.

To protect the residents of La Réunion, Valneva SE today announced an agreement with support from the local public health agency, the Agence Régionale de Santé La Réunion, to deliver 40,000 IXCHIQ® vaccine doses starting in early April, with an option to provide more.

IXCHIQ® is the world’s first licensed chikungunya vaccine to address this significant unmet medical need

This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé, to prioritize vaccination for adults aged 65 and over with co-morbidities.

Furthermore, IXCHIQ® remains available for purchase in France (mainland and overseas), as well as throughout Europe, the United States, and the U.K.

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented in a press release on March 24, 2025, “Chikungunya outbreaks spread rapidly, so it is crucial to vaccinate as many people as possible to help contain the virus."

"We have the capacity to supply more doses and will continue working closely with Agence Régionale de Santé La Réunion to manage this outbreak locally and prevent its spread to other regions through international travel.”

La Réunion is located east of Africa and Madagascar and is a favorite vaccination destination for international travelers.

Furthermore, Valneva recently announced an agreement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses, enabling the vaccine supply throughout Asia.

In the U.S., Chikungunya vaccines are commercially offered at travel clinics and pharmacies in 2025.